BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1301 related articles for article (PubMed ID: 24633452)

  • 21. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks.
    Höhne A; Mu L; Honer M; Schubiger PA; Ametamey SM; Graham K; Stellfeld T; Borkowski S; Berndorff D; Klar U; Voigtmann U; Cyr JE; Friebe M; Dinkelborg L; Srinivasan A
    Bioconjug Chem; 2008 Sep; 19(9):1871-9. PubMed ID: 18754574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer.
    Yu Z; Carlucci G; Ananias HJ; Dierckx RA; Liu S; Helfrich W; Wang F; de Jong IJ; Elsinga PH
    Amino Acids; 2013 Feb; 44(2):543-53. PubMed ID: 22833158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
    Craft JM; De Silva RA; Lears KA; Andrews R; Liang K; Achilefu S; Rogers BE
    Nucl Med Biol; 2012 Jul; 39(5):609-16. PubMed ID: 22261146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Preclinical Evaluation of
    Makris G; Bandari RP; Kuchuk M; Jurisson SS; Smith CJ; Hennkens HM
    Mol Imaging Biol; 2021 Feb; 23(1):52-61. PubMed ID: 32886303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
    Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR
    J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
    Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
    Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
    Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
    J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors.
    Schweinsberg C; Maes V; Brans L; Bläuenstein P; Tourwé DA; Schubiger PA; Schibli R; García Garayoa E
    Bioconjug Chem; 2008 Dec; 19(12):2432-9. PubMed ID: 19053304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative PET imaging study of
    Ferguson S; Wuest M; Richter S; Bergman C; Dufour J; Krys D; Simone J; Jans HS; Riauka T; Wuest F
    Nucl Med Biol; 2020; 90-91():74-83. PubMed ID: 33189947
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Rinne SS; Abouzayed A; Gagnon K; Tolmachev V; Orlova A
    Sci Rep; 2021 Feb; 11(1):3631. PubMed ID: 33574368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer.
    Gourni E; Del Pozzo L; Kheirallah E; Smerling C; Waser B; Reubi JC; Paterson BM; Donnelly PS; Meyer PT; Maecke HR
    Mol Pharm; 2015 Aug; 12(8):2781-90. PubMed ID: 26132879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues.
    Prasanphanich AF; Nanda PK; Rold TL; Ma L; Lewis MR; Garrison JC; Hoffman TJ; Sieckman GL; Figueroa SD; Smith CJ
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12462-7. PubMed ID: 17626788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
    Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
    Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee Sy; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
    Yang YS; Zhang X; Xiong Z; Chen X
    Nucl Med Biol; 2006 Apr; 33(3):371-80. PubMed ID: 16631086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.